OMADA HEALTH INC (OMDA) competitors & alternatives
Health Care · NASDAQ
OMADA HEALTH INC (OMDA)'s top competitors and alternatives — its most similar public companies — include HINGE HEALTH INC CLASS A (HNGE), Lilly (Eli) (LLY), WW International, Inc. (WW), Viking Therapeutics (VKTX), KAILERA THERAPEUTICS INC (KLRA), Dexcom (DXCM), LEXICON PHARMACEUTICALS INC (LXRX), NOVO NORDISK A S (NVO), PROTAGONIST THERAPEUTICS INC (PTGX), ALTIMMUNE INC (ALT), ADAPTHEALTH CORP (AHCO) and AMYLYX PHARMACEUTICALS INC (AMLX). These are OMADA HEALTH INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top OMDA competitors & alternatives
-
HINGE HEALTH INC CLASS AHNGEHealth Care
Hinge Health is an AI-driven digital MSK care platform that automates personalized pain treatment and physical therapy through motion-tracking technology and…
$79.08 (as of 2026-07-22) · market cap $6.5B
-
Lilly (Eli)LLYHealth Care
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss…
$1,163.01 (as of 2026-07-22) · market cap $1.09T
-
WW International, Inc.WWConsumer Discretionary
A global weight management and wellness company transitioning its legacy subscription-based coaching and nutrition programs to a digital-first platform in an…
$14.75 (as of 2026-07-22) · market cap $145M
-
Viking TherapeuticsVKTXHealth Care
Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market…
$37.31 (as of 2026-07-22) · market cap $4.3B
-
KAILERA THERAPEUTICS INCKLRAHealth Care
A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to…
$17.79 (as of 2026-07-22) · market cap $2.4B
-
DexcomDXCMHealth Care
Dexcom is a leader in continuous glucose monitoring (CGM) technology, providing essential real-time health data for diabetes management and metabolic health.
$71.43 (as of 2026-07-22) · market cap $28.8B
-
LEXICON PHARMACEUTICALS INCLXRXHealth Care
An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by…
$2.25 (as of 2026-07-22) · market cap $1.0B
-
NOVO NORDISK A SNVO
A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative…
$48.19 (as of 2026-07-22) · market cap $219.8B
-
PROTAGONIST THERAPEUTICS INCPTGXHealth Care
Protagonist Therapeutics is a biopharmaceutical firm leveraging a proprietary peptide-based platform to develop targeted therapies for inflammation,…
$135.44 (as of 2026-07-22) · market cap $8.7B
-
ALTIMMUNE INCALTHealth Care
A clinical-stage biopharmaceutical company developing dual-agonist peptide therapeutics targeting the massive obesity and metabolic disease markets.
$2.81 (as of 2026-07-22) · market cap $546M
-
ADAPTHEALTH CORPAHCOHealth Care
AdaptHealth delivers home medical equipment, supplies, and chronic disease management services directly to patients, focusing on sleep apnea, respiratory…
$10.88 (as of 2026-07-22) · market cap $1.5B
-
AMYLYX PHARMACEUTICALS INCAMLXHealth Care
Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric…
$17.70 (as of 2026-07-22) · market cap $2.0B
Not quite? Describe exactly what you want →
Peers are OMADA HEALTH INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: OMADA HEALTH INC (OMDA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.